Lipid-Bound Hsp70 Detection via cmHsp70.1 Monoclonal Antibody
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ELISA assays for detecting Hsp70 in serum are inefficient and not sensitive enough to accurately quantify lipid-bound exosomal Hsp70, leading to variable results and limited utility as a biomarker for tumor detection and diagnosis.
Innovation Solution
Development of a novel lipHsp70 sandwich ELISA using the cmHsp70.1 monoclonal antibody, which specifically detects the inducible form of Hsp70 without cross-reacting with the constitutive form Hsc70, allowing for efficient detection of lipid-bound Hsp70 in exosomes and plasma membrane of tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If commercial ELISA kits are used to detect Hsp70 in serum, then the detection can be performed with standard protocols, but the sensitivity and accuracy for lipid-bound exosomal Hsp70 are insufficient
Solution Approach 1:
The patent modifies the ELISA assay parameters specifically for lipid-bound Hsp70 detection by using a monoclonal antibody (cmHsp70.1) that recognizes a conformational epitope exposed only on lipid-bound Hsp70. This parameter change in antibody selection and epitope recognition enables specific detection of lipid-bound forms while maintaining assay reliability
Solution Approach 2:
The patent introduces a specific monoclonal antibody (cmHsp70.1) as an intermediary that selectively binds to conformational epitopes on lipid-bound Hsp70. This intermediary enables the detection system to specifically recognize and quantify lipid-bound exosomal Hsp70 without cross-reacting with soluble Hsp70, thereby improving measurement precision
2Productivity
If standard ELISA assays are used, then the procedure is simple and fast, but the recovery rate for lipid-bound Hsp70 is low
Solution Approach 1:
The patent changes the critical parameter of antibody selection to cmHsp70.1, which specifically recognizes conformational epitopes on lipid-bound Hsp70. This parameter change increases the recovery rate from approximately 10% with standard kits to about 75%, while the assay procedure remains relatively simple and fast
3Measurement precision
If antibodies against Hsp70 are used for detection, then Hsp70 levels can be measured, but cross-reactivity with Hsc70 reduces specificity
Solution Approach 1:
The patent applies local quality by designing an antibody (cmHsp70.1) that recognizes a specific local feature - a conformational epitope that is exclusively exposed on lipid-bound inducible Hsp70 but not on constitutive Hsc70 or soluble Hsp70. This localized epitope recognition eliminates cross-reactivity and improves measurement precision
Solution Approach 2:
The patent changes the antibody specificity parameter by selecting cmHsp70.1 that targets a conformational epitope unique to lipid-bound inducible Hsp70. This parameter change in antibody selection eliminates cross-reactivity with Hsc70 and enables specific detection of the inducible form
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipHsp70 assay achieves a recovery rate of approximately 75% for lipid-bound Hsp70, significantly higher than commercial ELISA kits, providing a more accurate and sensitive method for detecting Hsp70 levels in serum, particularly in tumor patients and multiple sclerosis patients, with improved specificity and sensitivity.
Implementation Method 1
the level of free and lipid-bound (exosomal) heat shock protein 70 (Hsp70) is determined by way of detecting a particular conformational epitope of Hsp70
Data Source
AI summary
Provided is a novel kit and assay for free and lipid-bound (exosomal) Hsp70. In particular, an ELISA is described for determining the level of Hsp70 in sample derived from a body fluid of a subject, characterized in that the level of Hsp70 is determined by an anti-Hsp70 antibody.